Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"
- PMID: 23704555
- DOI: 10.1126/science.1235505
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"
Abstract
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) reported that bexarotene rapidly reduces β-amyloid (Aβ) levels and plaque burden in two mouse models of Aβ deposition in Alzheimer's disease (AD). We now report that, although bexarotene reduces soluble Aβ40 levels in one of the mouse models, the drug has no impact on plaque burden in three strains that exhibit Aβ amyloidosis.
Comment in
-
Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".Science. 2013 May 24;340(6135):924-g. doi: 10.1126/science.1234114. Science. 2013. PMID: 23704556 Free PMC article.
Comment on
-
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.Science. 2012 Mar 23;335(6075):1503-6. doi: 10.1126/science.1217697. Epub 2012 Feb 9. Science. 2012. PMID: 22323736 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous